ORDERING RELENZA — HOW TO ORDER RELENZA

Guideline 4: Storage

When deciding where to store RELENZA, ensure that all recommended storage requirements are met. Consider some of these storage suggestions:

• Organization health clinic
• Physician’s office
• Retail pharmacy
• Community health clinic
• Distributors
• Mail pharmacy
• Locate a storage partner

Once a location is chosen, practice the following guidelines for maintaining the storage locations:

• Include DEA number on all boxes
• Keep a controlled substance registration on file
• Follow RELENZA product storage guidelines
• Follow US Pharmacopeia storage guidelines
• Provide adequate space to meet quantity and pandemic plan demands

To keep track of orders and storage, download the Antiviral Stock Control Spread Sheet pdf.

RELENZA should be stored at a room temperature of 77°F (25°C); excursions permitted to 59°F to 86°F (15°C to 30°C). Keep out of reach of children. Product shelf life: 5 years.[38]

For storage guidelines of US Pharmacopeia, click here.

Guideline 5: Distribution

 
Important Safety Information About RELENZA

• Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  
• RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  
• Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  
• Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  
• If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  
• Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  
• Please see complete Prescribing Information for RELENZA